 MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced the successful dosing of the first patient in the expansion cohort of the Phase 1 alloSHRINK trial for CYAD-101, the Companys allogeneic T cell receptor TCR inhibitory molecule TIM-based, non-gene edited CAR T candidate for the treatment of refractory metastatic colorectal cancer mCRC. 